{"prompt": "['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 60 of 92', 'CR845-CLIN3102', '8.4', 'Interim Analysis', '8.4.1', 'Sample Size Re-estimation', 'An unblinded interim analysis for sample size re-estimation will be conducted when', 'approximately 50% of the first 350 patients have been randomized and have either', 'completed the 12-week Double-blind Treatment Period or have discontinued from', 'double-blind treatment early. The planned interim assessment will be conducted by an', 'IDMC. An unblinded statistician who will not be part of the study team will provide', 'results of the interim analysis to the IDMC members. Members of the IDMC will not', 'participate in the DSMB and will not be members of the study team. During the interim', 'assessment, the study team will remain blinded to the data; however, the IDMC will', 'receive unblinded summary results to implement the decision rule for sample size', 're-estimation. The IDMC will only communicate the decision to either keep the original', 'sample size or to increase it; no other results will be provided to blinded staff. The', 'DSMB will be made aware of the decision, but not given the results that were the basis of', 'the decision.', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 62 of 95']['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 61 of 92', 'CR845-CLIN3102', '8.4.2', 'Safety Data Review', 'The operation of the DSMB will be governed by a charter that will describe the meeting', 'frequency, procedures, and requirements for reporting its observations to the Sponsor.', 'Safety data will be reviewed on an ongoing basis by the Sponsor and a DSMB. In order', 'to actively monitor patient safety, a prospective approach will be taken to collect and', 'analyze specific adverse events designated as adverse events of special interest.', '8.5', 'Analysis Populations', 'The Enrolled Population is defined as the group of patients who sign informed consent.', 'The ITT Population is defined as the group of patients who are randomized to a treatment', 'group.', 'The Double-blind Safety Population is defined as the group of randomized patients who', 'received at least 1 dose of double-blind study drug during the Double-blind Treatment', 'Period.', 'Following the intent-to-treat principle, patients in the ITT population will be analyzed', 'according to their randomized treatment, regardless of the actual treatment received.', 'Patients in the Double-blind Safety Population will be analyzed according to the actual', 'treatment received. The Double-blind Safety Population will be used to analyze all safety', 'endpoints collected during the Double-blind Phase, while the ITT Population will be used', 'to analyze all efficacy endpoints collected during the Double-blind Phase.', 'The Per-Protocol Population is defined as the subset of patients in the ITT Population', 'who do not have any major protocol deviations that could affect the efficacy analyses of', 'the double-blind data. An analysis of the primary and secondary efficacy variables for', 'the Per-Protocol Population will be performed.', 'Key exclusions from the Per-Protocol population include patients who:', 'Received less than 80% of the planned study drug doses', 'Had a mean baseline Worst Itching Intensity score <= 4.0', 'Had a missing average 24-hour weekly Worst Itching NRS score for >25% of', 'study weeks', 'Had significant amounts of restricted and prohibited medications (Section 6.4.9)', 'based on medical review', 'Received a different treatment than the treatment to which they were randomized', 'Inclusion in the Per-Protocol Population will be determined prior to unblinding the data.', 'The Open-label Safety Population is defined as the group of patients who receive at least', '1 dose of study drug in the Open-label Phase. The Open-label Safety Population will be', 'used to analyze all safety endpoints collected during the Open-label Phase, and during', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 63 of 95']['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 62 of 92', 'CR845-CLIN3102', 'exposure to CR845 combining data from both the Double-blind and the', 'Open-label Phases.', '8.6', 'Statistical Summary and Analysis', '8.6.1', 'Patient Disposition', 'For the Double-blind Phase, the number of patients enrolled, treated, completed, or', 'discontinued from the study, along with the reason for discontinuation, will be', 'summarized overall and by treatment group.', 'For all categories of patients (except for the screened patients), percentages will be', 'calculated using the number of enrolled patients as the denominator.', 'In addition, the number of patients in each analysis population will be tabulated.', '8.6.2', 'Protocol Deviations', 'Protocol deviations will be identified in several ways: through programmatic checks,', 'through medical reviews, and by clinical research associates during site monitoring.', 'Protocol deviations will be classified as minor or major prior to the database lock. Major', 'protocol deviations will be summarized by treatment group. All protocol deviations will', 'be listed.', '8.6.3', 'Demographic and Baseline Characteristics', 'Demographic and baseline patient characteristics will be summarized overall and by', 'treatment group and will include age at screening, age category (<45, 45 to >65, 65 to', '<75, 75), gender, ethnicity, race, prescription dry body weight (kg). Height will not be', 'collected.', 'Baseline characteristics of the disease will also be summarized overall and by treatment', 'group, and will include variables such as etiology of chronic kidney disease, years since', 'ESRD, duration of pruritus, and time on chronic hemodialysis.', '8.6.4', 'Medical History', 'Medical history data will be coded using Medical Dictionary for Regulatory Activities', '(MedDRA) and summarized by MedDRA System Organ Class (SOC), Preferred Term,', 'and treatment group. The data will also be listed, including the verbatim investigator', 'description of the relevant medical condition, the coded terms (SOC, Preferred Term),', 'start date, end date, and whether or not the condition is ongoing.', 'A separate coding listing will be created with all the distinct levels of SOC, Preferred', 'Terms, and the verbatim investigator description reported in the study. Sorting will be', 'alphabetically by SOC, Preferred Term, and then verbatim description.', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 64 of 95']\n\n###\n\n", "completion": "END"}